FDA Advisors Recommend Galleri Multicancer Blood Test

An FDA advisory committee narrowly voted in favour of the Galleri multicancer early detection blood test, with margins of 6-4 and 7-2 (one abstention) from the molecular and clinical genetics panel. Panellists expressed clear reservations, reflecting ongoing uncertainty about whether detecting cell-free DNA signals across dozens of tumour types actually reduces cancer mortality rather than merely finding more disease. A favourable FDA decision would make Galleri the first broadly marketed multicancer screening test in the United States, a potential turning point for how population-level cancer screening is organised.